ESK-001-002
13 evidence topics · 2 sources
Objective
Location and study date
Study start and completion dates in the ClinicalTrials.gov record
“Study Start (Actual) 2022-03-17” (opens the source at this quote in a new tab)
“Primary Completion (Actual) 2022-06-30” (opens the source at this quote in a new tab)
“Study Completion (Actual) 2022-09-20” (opens the source at this quote in a new tab)
“First Submitted 2022-03-30” (opens the source at this quote in a new tab)
“First Posted 2022-04-15” (opens the source at this quote in a new tab)
Completion dates estimated at registration, April 2022, superseded in September 2022
Site in Glendale, California, in the ClinicalTrials.gov record
“This study has 1 location” (opens the source at this quote in a new tab)
“Alumis Central Site” (opens the source at this quote in a new tab)
| Field | Quoted record |
|---|---|
| Location | “Glendale, California, United States, 91206” |
Recruitment and results status in the ClinicalTrials.gov record
| Field | Quoted record |
|---|---|
| Overall status | “Completed” |
| Results | “No Results Posted” |
| Last update posted | “2023-05-09” |
Study design
Design details in the ClinicalTrials.gov record
| Field | Quoted record |
|---|---|
| Other study ID numbers | “ESK-001-002” |
| Conditions | “Pharmacokinetics” |
| Primary purpose | “Basic Science” |
| Allocation | “Randomized” |
| Interventional model | “Crossover Assignment” |
| Masking | “None (Open Label)” |
Four-period crossover with an 18-day stay in the clinical research unit in the registered description
Eligibility criteria
Inclusion and exclusion criteria in the ClinicalTrials.gov record
| Criterion | Quoted record |
|---|---|
| Inclusion: age and health | “Healthy Men and woman age 18-60” |
| Inclusion: consent | “Able to provide written informed consent” |
| Inclusion: pregnancy and lactation | “Females can not be pregnant or lactating” |
| Exclusion: prior exposure | “Prior exposure to ESK-001” |
| Exclusion: malignancy | “History of malignancy within the last 10 years” |
| Exclusion: viral infection | “Positive for HIV, Hepatitis B or C” |
| Exclusion: tuberculosis | “History of tuberculosis” |
| Exclusion: alcohol or drugs | “Positive test for alcohol or drugs” |
| Ages eligible for study | “18 Years to 60 Years (Adult )” |
| Sexes eligible for study | “All” |
| Accepts healthy volunteers | “Yes” |
Treatment
Liquid, fasted tablet, fed tablet, and tablet with rabeprazole arms in the ClinicalTrials.gov record
Study outcomes
Rationale for using pharmacokinetic parameters as the primary endpoint
Primary and secondary outcome measures in the ClinicalTrials.gov record
Statistical analysis description
Number of participants (Planned and analyzed)
Actual enrollment in the ClinicalTrials.gov record
Enrollment estimated at registration, April 2022, superseded in May 2023
Description of analysis sets
No evidence found.
Results
Participant disposition
No evidence found.
Baseline characteristics
No evidence found.
Efficacy results
No evidence found.
Health-related quality of life and patient-reported outcomes
No evidence found.
Safety results
No evidence found.
Study limitations
Summary
- The relative bioavailability, food effect, and gastric acid reduction comparisons (liquid, tablet fasted, tablet fed, and tablet with rabeprazole) have no posted results, and the report holds no published results; the ClinicalTrials.gov record reads “No Results Posted”.
- The study was a single-center, open-label crossover study; the registered description calls it partly randomized and plans 15 healthy participants, and actual enrollment was 14.
- Each participant received a single dose on 4 occasions, so the comparisons rest on single-dose pharmacokinetics in healthy adults aged 18 to 60 years.